NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital promotes Ksenija Pavletic to General Partner
Paris, France, October 15th, 2025 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, today announced the promotion of Ksenija Pavletic to General Partner, reinforcing the firm’s senior leadership team as it continues to...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to...
Jeito Capital appoints Pascal Touchon as Operating Partner
Pascal Touchon will reinforce Jeito's expertise by bringing over 35 years of global experience in...
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
Proceeds from the financing will advance ReproNovo’s lead candidates RPN-001 (leflutrozole) and...
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick...
Jeito Capital Strengthens Leadership for Next Chapter of Growth:Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 2024 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund...
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases
Proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase 2...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.